[1] Mozaffarian D, Benjamin E J, Go A S, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association [J]. Circulation, 2016, 133: e38-e360.

[2] Broughton K M, Sussman M A. Empowering adult stem cells for myocardial regeneration V2.0: success in small steps [J]. Circulation Research, 2016, 118: 867-880.
[3] Tabar V, Studer L. Pluripotent stem cells in regenerative medicine: challenges and recent progress [J]. Nature Reviews Genetics, 2014, 15: 82-92.
[4] Yamanaka S. Induced pluripotent stem cells: past, present, and future [J]. Cell Stem Cell, 2012, 10: 678-684.
[5] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors [J]. Cell, 2006, 126: 663-676.
[6] Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors [J]. Cell, 2007, 131: 861-872.
[7] Yu J, Vodyanik M A, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells [J]. Science, 2007, 318: 1917-1920.
[8] Zhao X Y, Li W, L¨u Z, et al. Ips cells produce viable mice through tetraploid complementation[J]. Nature, 2009, 461: 86-90.
[9] Kang L, Wang J, Zhang Y, et al. Ips cells can support full-term development of tetraploid blastocyst-complemented embryos [J]. Cell Stem Cell, 2009, 5: 135-138.
[10] Harding J, Roberts R M, Mirochnitchenko O. Large animal models for stem cell therapy [J]. Stem Cell Research & Therapy, 2013, 4: 23.
[11] Hochedlinger K, Jaenisch R. Induced pluripotency and epigenetic reprogramming [J]. Cold Spring Harb Perspect Bio, 2015, 7(12): a019448.
[12] Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds [J]. Science, 2013, 341: 651-654.
[13] Raab S, Klingenstein M, Liebau S, et al. A comparative view on human somatic cell sources for ipsc generation [J]. Stem Cells International, 2014, 2014: 768391.
[14] Dubois N C, Craft A M, Sharma P, et al. Sirpa is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells [J]. Nature Biotechnology, 2011, 29: 1011-1018.
[15] Laflamme M A, Chen K Y, Naumova A V, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts[J]. Nature
Biotechnology, 2007, 25: 1015-1024.
[16] Burridge P W, Matsa E, Shukla P, et al. Chemically defined generation of human cardiomyocytes[J]. Nature Methods, 2014, 11: 855-860.
[17] Lian X, Bao X, Zilberter M, et al. Chemically defined, albumin-free human cardiomyocyte generation [J]. Nature Methods, 2015, 12: 595-596.
[18] Tohyama S, Hattori F, Sano M, et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes [J]. Cell Stem Cell, 2013, 12: 127-137.
[19] Orlova V V, Van Den Hil F E, Petrus-Reurer S, et al. Generation, expansion and functional analysis of endothelial cells and pericytes derived from human pluripotent stem cells [J]. Nature Protocols, 2014, 9: 1514-1531.

[20] Hu S, Wilson K D, Ghosh Z, et al. Microrna-302 increases reprogramming efficiency via repression of nr2f2 [J]. Stem Cells, 2013, 31: 259-268.
[21] Li Z, Hu S, Ghosh Z, et al. Functional characterization and expression profiling of human induced pluripotent stem cell- and embryonic stem cell-derived endothelial cells [J]. Stem Cells and Development, 2011, 20: 1701-1710.
[22] Marchand M, Anderson E K, Phadnis S M, et al. Concurrent generation of functional smooth muscle and endothelial cells via a vascular progenitor [J]. Stem Cells Translational Medicine, 2014, 3: 91-97.
[23] Gu M, Mordwinkin N M, Kooreman N G, et al. Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism [J]. European Heart Journal, 2015, 36: 806-816.
[24] Uygur A, Lee R T. Mechanisms of cardiac regeneration [J]. Developmental Cell, 2016, 36: 362-374.
[25] Nelson T J, Martinez-Fernandez A, Yamada S, et al. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells [J]. Circulation, 2009, 120: 408-416.
[26] Mauritz C, Martens A, Rojas S V, et al. Induced pluripotent stem cell (ipsc)-derived flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute
myocardial infarction [J]. European Heart Journal, 2011, 32: 2634-2641.
[27] Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model [J]. Circulation, 2012, 126: S29-S37.
[28] Funakoshi S, Miki K, Takaki T, et al. Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human ipsc-derived cardiomyocytes [J]. Scientific Reports, 2016, 6: 19111.
[29] Gu M, Nguyen P K, Lee A S, et al. Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by
paracrine activation [J]. Circulation Research, 2012, 111: 882-893.
[30] Xiong Q, Ye L, Zhang P, et al. Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction
remodeling [J]. Circulation, 2013, 127: 997-1008.
[31] Dai B, Huang W, Xu M, et al. Reduced collagen deposition in infarcted myocardium facilitates induced pluripotent stem cell engraftment and angiomyogenesis for improvement of left ventricular function [J]. Journal of the American College of Cardiology, 2011, 58: 2118-2127.
[32] Masumoto H, Ikuno T, Takeda M, et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration [J]. Scientific Reports, 2014, 4: 6716.
[33] Ye L, Chang Y H, Xiong Q, et al. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells [J]. Cell Stem Cell, 2014, 15: 750-761.
[34] Sanchez-Freire V, Lee A S, Hu S,et al. Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells [J]. Journal of the American College of Cardiology, 2014, 64: 436-448.

[35] Birket M J, Mummery C L. Pluripotent stem cell derived cardiovascular progenitors—a developmental perspective [J]. Developmental Biology, 2015, 400: 169-179.
[36] Lundy S D, Zhu W Z, Regnier M, et al. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells [J]. Stem Cells and Development, 2013, 22: 1991-2002.
[37] Andrews P W, Baker D, Benvinisty N, et al. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: international stem cell banking
initiative (iscbi) [J]. Regenerative Medicine, 2015, 10: 1-44.